Do Insurance Plans Cover Vascepa?
Most U.S. insurance plans, including Medicare Part D and many commercial plans from providers like UnitedHealthcare, Aetna, and Blue Cross Blue Shield, cover Vascepa (icosapent ethyl) for FDA-approved uses like reducing cardiovascular risk in patients with high triglycerides despite statin therapy.[1] Coverage typically requires prior authorization to confirm medical necessity, such as documented triglyceride levels above 150 mg/dL and no uncontrolled diabetes.[2]
How Much Do Patients Pay with Coverage?
Copays for covered patients average $40-$60 per month at retail pharmacies, though tiers vary—Vascepa often falls into Tier 3 or 4, leading to 25-50% coinsurance.[3] Medicare beneficiaries pay around $45 monthly after the deductible, with low-income subsidies reducing it further via Extra Help.[1][4]
What If Insurance Denies Coverage?
Denials occur if triglycerides are below threshold, off-label use (e.g., standalone hypertriglyceridemia), or cheaper generics like lovaza are preferred.[2] Patients can appeal with lab results and physician letters; success rates exceed 70% for cardiovascular indications.[5] Without coverage, list price is $300-$400 for 120 capsules (4-week supply).[3]
Medicare Coverage Specifics
Medicare Part D covers Vascepa at 93% of plans, with average premiums under $50/month factoring it in.[1][4] Part B may cover it in hospital outpatient settings. Look up your plan's formulary on Medicare.gov to confirm tier and restrictions.
Commercial Insurance Variations
Coverage is widespread but plan-specific: 85% of commercial policies include it, often with step therapy requiring fish oil trials first.[3] Employer-sponsored plans from CVS Caremark or Express Scripts networks align closely with Medicare tiers.
Manufacturer Savings Programs
Eligible commercially insured patients pay $9/month via the Vascepa Savings Card, even if tiered high; max $16,500/year savings.[6] Uninsured or government-insured patients qualify for patient assistance programs covering full costs based on income (under 400% FPL).[7]
When Does Vascepa's Patent Expire?
Patents on Vascepa's pure EPA formulation extend to 2030, delaying generics and sustaining high list prices.8 Check DrugPatentWatch.com for litigation updates on challenges from Dr. Reddy's and others.8
[1]: Medicare.gov Plan Finder (2024 data)
[2]: FDA Label for Vascepa
[3]: GoodRx pricing analysis (Sep 2024)
[4]: CMS Medicare Part D formulary data
[5]: CoverMyMeds appeal statistics
[6]: Vascepa.com Savings Card terms
[7]: Amarin Patient Assistance Program